Natrol bulks up
This article was originally published in The Tan Sheet
Executive Summary
Supplement firm's sales increase 9.6% to $20.7 mil. in the second quarter (ended June 30), with earnings of $769,000 compared to a net loss of $246,000 in the prior-year period. Natrol has focused on its core Natrol brand following the divestment of multi-level and direct marketing businesses Annasa and Tamasa in January. Weight-loss product sales as well as the consolidation of its Prolab sports nutrition business into the firm's Chatsworth, Calif. corporate headquarters also contributed to profitability, President Elliot Balbert maintained...
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.